Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Hereditary angioedema type 1 (HAE 1) is a form of hereditary angioedema characterized by acute edema in subcutaneous tissues, viscera and/or the upper airway.
Biomarker and diagnostic research for hereditary angioedema type 1 has been reported in the published literature.
Estimated prevalence: 1-9 in 100,000 (Uncommon).
17 clinical trials registered, 4 recruiting. Interventions under study include drug therapy, other interventions, biologic therapy, and gene therapy. Pipeline includes 1 PHASE4, 8 PHASE3, 2 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06960213](https://clinicaltrials.gov/study/NCT06960213) |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 3:02 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
STOP-HAE: A Phase 3 Study of ADX-324 in HAE |
PHASE3 |
ADARx Pharmaceuticals, Inc. |
RECRUITING |
[NCT07428499](https://clinicaltrials.gov/study/NCT07428499) | Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE) | PHASE3 | ADARx Pharmaceuticals, Inc. | RECRUITING |
[NCT07046806](https://clinicaltrials.gov/study/NCT07046806) | Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients | PHASE1 | Institute for Asthma and Allergy | RECRUITING |
[NCT06573723](https://clinicaltrials.gov/study/NCT06573723) | Institutional Registry of Rare Diseases | — | Hospital Italiano de Buenos Aires | RECRUITING |
45 publications have been identified in PubMed for hereditary angioedema type 1. Research spans Clinical Trial Publication (24%), Epidemiology / Natural History (24%), and Case Report / Case Series (18%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 11 | 24% |
Disease patterns and progression | 11 | 24% |
Patient case studies | 8 | 18% |
Research summaries | 7 | 16% |
Testing and diagnosis research | 3 | 7% |
Laboratory research | 3 | 7% |
Other research | 2 | 4% |
Jones D (2026). [PMID: 41533199](https://pubmed.ncbi.nlm.nih.gov/41533199/). *Clin Exp Med*. [Epidemiology / Natural History]
Hisamoto T (2026). [PMID: 41850960](https://pubmed.ncbi.nlm.nih.gov/41850960/). *J Dermatol Sci*. [Case Report / Case Series]
Aykan FS (2026). [PMID: 41814599](https://pubmed.ncbi.nlm.nih.gov/41814599/). *Allergol Immunopathol (Madr)*. [Epidemiology / Natural History]
Manning ME (2026). [PMID: 41802598](https://pubmed.ncbi.nlm.nih.gov/41802598/). *Ann Allergy Asthma Immunol*. [Clinical Trial Publication]
Kural RF (2026). [PMID: 41742205](https://pubmed.ncbi.nlm.nih.gov/41742205/). *Orphanet J Rare Dis*. [Diagnostic / Biomarker]
Maurer M (2026). [PMID: 41865747](https://pubmed.ncbi.nlm.nih.gov/41865747/). *Lancet Haematol*. [Clinical Trial Publication]
Aygören-Pürsün E (2026). [PMID: 41865746](https://pubmed.ncbi.nlm.nih.gov/41865746/). *Lancet Haematol*. [Clinical Trial Publication]
Cosme Ferreira S (2026). [PMID: 41662830](https://pubmed.ncbi.nlm.nih.gov/41662830/). *Acta Med Port*. [Case Report / Case Series]
Boch K (2026). [PMID: 41782867](https://pubmed.ncbi.nlm.nih.gov/41782867/). *Front Immunol*. [Epidemiology / Natural History]
Bernstein JA (2025). [PMID: 40504359](https://pubmed.ncbi.nlm.nih.gov/40504359/). *Adv Ther*. [Clinical Trial Publication]